153 related articles for article (PubMed ID: 36798455)
1. Simulating the Evolution of Signaling Signatures during CART-Cell - Tumor Cell Interactions.
Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
ArXiv; 2023 Feb; ():. PubMed ID: 36798455
[TBL] [Abstract][Full Text] [Related]
2. Simulating the Evolution of Signaling Signatures During CART-Cell and Tumor Cell Interactions.
Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083755
[TBL] [Abstract][Full Text] [Related]
3. CRISPR Takes the Front Seat in CART-Cell Development.
Manriquez-Roman C; Siegler EL; Kenderian SS
BioDrugs; 2021 Mar; 35(2):113-124. PubMed ID: 33638865
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
Ramakrishna S; Highfill SL; Walsh Z; Nguyen SM; Lei H; Shern JF; Qin H; Kraft IL; Stetler-Stevenson M; Yuan CM; Hwang JD; Feng Y; Zhu Z; Dimitrov D; Shah NN; Fry TJ
Clin Cancer Res; 2019 Sep; 25(17):5329-5341. PubMed ID: 31110075
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN
Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation.
Holland EM; Molina JC; Dede K; Moyer D; Zhou T; Yuan CM; Wang HW; Stetler-Stevenson M; Mackall C; Fry TJ; Panch S; Highfill S; Stroncek D; Little L; Lee DW; Shalabi H; Yates B; Shah N
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35534047
[TBL] [Abstract][Full Text] [Related]
8. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
10. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
11. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
14. Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.
Dannenfelser R; Allen GM; VanderSluis B; Koegel AK; Levinson S; Stark SR; Yao V; Tadych A; Troyanskaya OG; Lim WA
Cell Syst; 2020 Sep; 11(3):215-228.e5. PubMed ID: 32916097
[TBL] [Abstract][Full Text] [Related]
15. CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.
Filley AC; Henriquez M; Dey M
Front Oncol; 2018; 8():453. PubMed ID: 30386740
[TBL] [Abstract][Full Text] [Related]
16. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review.
Sharma R; Suravarjhula L; Banerjee M; Kumar G; Kumar N
Curr Drug Res Rev; 2023; 15(3):241-261. PubMed ID: 36825696
[TBL] [Abstract][Full Text] [Related]
18. Driving cars to the clinic for solid tumors.
Castellarin M; Watanabe K; June CH; Kloss CC; Posey AD
Gene Ther; 2018 Jun; 25(3):165-175. PubMed ID: 29880908
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
